M Z Sharkawi Marco, H Amin Noha, R Mohamed Norhan, S Zaki Shimaa, R Hemeda Loah
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy , Beni-Suef University Alshaheed Shehata Ahmed Hegazy St. , Beni-Suef , 62514, Egypt.
Department of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, 62514, Egypt.
Sci Rep. 2025 Aug 14;15(1):29894. doi: 10.1038/s41598-025-15078-6.
Multiple myeloma (MM) is a blood cancer that, unfortunately, has a high morbidity and mortality rate. The VMP regimen, which includes bortezomib (BOR), melphalan (MEL), and prednisolone (PRD), is a safe and effective salvage regimen for refractory or relapsed MM. Up to now, there is no established analytical method to determine the VMP regimen, nor has any study investigated the kinetic interactions among its components, thereby highlighting the need for further clinical investigation. In light of this, an environmentally friendly, fast, sensitive, and precise LC-MS/MS method was established to determine bortezomib, melphalan, prednisolone, and sildenafil (an internal standard) simultaneously as part of the in vivo pharmacokinetics research carried out on rats. The established LC-MS/MS method was applied using a mobile phase composed of a mixture of methanol: 0.1% aqueous solution of formic acid and a ZORBAX Eclipse Plus C18 column (4.6 mm × 150 mm, 5 μm) as a stationary phase. The cited drugs were ionized through positive ionization and detected using multi-reaction monitoring (MRM) mode with the following precursor→product transitions: m/z 367.3→226.3 for BOR, m/z 305.0→168.2 for MEL, m/z 545.0→147.5 for PRD, and m/z 475.3→283.4 for SIL. Following FDA guidelines, the developed method was validated and showed acceptable ranges. Subsequently, it was employed in an in vivo investigation using rats, where the quantitative assessment of each drug was performed following both single and combined treatment. This allowed for the investigation of potential drug-drug interactions and the calculation of all pharmacokinetic parameters to monitor the therapeutic effects of those medications. To ensure the safety and environmental friendliness of the developed method, four assessment tools were applied: the assessment of green profile (AGP), blue applicability grade index (BAGI), analytical greenness metric for sample preparation (AGREEprep), and green analytical procedure index (GAPI).
多发性骨髓瘤(MM)是一种血液癌症,不幸的是,其发病率和死亡率都很高。包含硼替佐米(BOR)、美法仑(MEL)和泼尼松龙(PRD)的VMP方案是一种用于难治性或复发性MM的安全有效的挽救方案。到目前为止,尚无确定VMP方案的既定分析方法,也没有研究调查其成分之间的动力学相互作用,因此凸显了进一步临床研究的必要性。有鉴于此,建立了一种环境友好、快速、灵敏且精确的液相色谱-串联质谱(LC-MS/MS)方法,用于同时测定硼替佐米、美法仑、泼尼松龙和西地那非(内标),作为对大鼠进行的体内药代动力学研究的一部分。所建立的LC-MS/MS方法采用由甲醇与0.1%甲酸水溶液的混合物组成的流动相,并使用ZORBAX Eclipse Plus C18柱(4.6 mm×150 mm,5μm)作为固定相。所引用的药物通过正离子化进行离子化,并使用多反应监测(MRM)模式进行检测,具有以下前体→产物转换:BOR为m/z 367.3→226.3,MEL为m/z 305.0→168.2,PRD为m/z 545.0→147.5,SIL为m/z 475.3→283.4。按照美国食品药品监督管理局(FDA)的指导方针,对所开发的方法进行了验证,并显示出可接受的范围。随后,将其用于对大鼠的体内研究,在单次和联合治疗后对每种药物进行定量评估。这使得能够研究潜在的药物-药物相互作用,并计算所有药代动力学参数以监测这些药物的治疗效果。为确保所开发方法的安全性和环境友好性,应用了四种评估工具:绿色概况评估(AGP)、蓝色适用性等级指数(BAGI)、样品制备的分析绿色度指标(AGREEprep)和绿色分析程序指数(GAPI)。